Company Profile

Histogen Inc
Profile last edited on: 9/12/22      CAGE: 50XD3      UEI: LJ9GNAKK89Q1

Business Identifier: Regenerative medicine: naturally-produced products from newborn fibroblasts grown in proprietary bioreactor
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

10655 Sorrento Valley Road
San Diego, CA 92121
   (858) 526-3100
Location: Single
Congr. District: 52
County: San Diego

Public Profile

Histogen Inc (NASDAQ:HSTO) is a regenerative medicine company developing patented technologies designed to stimulate the body’s stem cells to regenerate tissues and restore youthful function. The Company’s lead therapeutic product has induced hair growth in multiple clinical trials, addressing a multibillion dollar global market. Additional applications of Histogen’s technology span multiple therapeutic and aesthetic areas including skin care, orthopedics, wound healing, and dermal fillers. Histogen Inc., therapeutics are based on the products of fibroblast cells grown under simulated embryonic conditions. Offering HST-001, a hair stimulating complex in Phase 1b/2a clinical trial for treatment of androgenic alopecia (hair loss); HST-003, a human extracellular matrix, in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; and Emricasan, an orally active pan-caspase inhibitor in Phase 1 clinical trial for the treatment of COVID-19. The company's pre-clinical programs include HST-004, a cell conditioned media (CCM) solution to treat spinal disc repair; and HST-002, a human-derived collagen and extracellular matrix dermal filler for the treatment of facial folds and wrink

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2017 2 NSF $1,019,999
Project Title: A Novel Wound Dressing for Infection Control and Tissue Regeneration

Key People / Management

  Gail K Naughton -- Founder & Former CEO

  Richard W Pascoe -- CEO, Pres & Director

  Mark Baumgartner -- Director of Engineering

  Susan Baxter -- Executive Director

  Moya Daniels -- EVP & Head of Regulatory, Quality and Clinical Operations

  Stephen Hill -- Director of Finance/Controller

  Mark A Hubka -- Director of Clinical Affairs

  Martin Latterich -- Vice President of Technical Operations

  Gail K Naughton -- Founder, Chief Scientific Officer & Chief Bus. Officer

  Eileen Naughton Brandt -- Director of Corporate Communications

  Marsha Rolle

  Michael P Zimber -- Direcror of Applied Research